SMMT – summit therapeutics inc. (US:NASDAQ)

DELAYED


Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low


VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close

YTD

1 Day

SMMT

SPY

QQQ

Swipe to see more

Main News & Impact Reports

Date

Time

Symbol

Headline

Impact

11/18

12:00 pm

smmt

Rating for SMMT

Low Report

Rating for SMMT

Report

11/18

12:00 pm

smmt

Rating for SMMT

Low Report

Rating for SMMT

Report

11/18

09:00 am

smmt

Summit Therapeutics (NASDAQ:SMMT) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.

Low Report

Summit Therapeutics (NASDAQ:SMMT) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.

Report

11/18

09:00 am

smmt

Summit Therapeutics (NASDAQ:SMMT) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.

Low Report

Summit Therapeutics (NASDAQ:SMMT) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.

Report

11/17

04:21 pm

smmt

Summit Therapeutics initiated with a Peer Perform at Wolfe Research

Low Report

Summit Therapeutics initiated with a Peer Perform at Wolfe Research

Report

11/17

04:21 pm

smmt

Summit Therapeutics initiated with a Peer Perform at Wolfe Research

Low Report

Summit Therapeutics initiated with a Peer Perform at Wolfe Research

Report

10/22

09:28 am

smmt

Summit Therapeutics (NASDAQ:SMMT) had its "buy" rating reaffirmed by analysts at Guggenheim. They now have a $40.00 price target on the stock.

Low Report

Summit Therapeutics (NASDAQ:SMMT) had its "buy" rating reaffirmed by analysts at Guggenheim. They now have a $40.00 price target on the stock.

Report

10/22

09:28 am

smmt

Summit Therapeutics (NASDAQ:SMMT) had its "buy" rating reaffirmed by analysts at Guggenheim. They now have a $40.00 price target on the stock.

Low Report

Summit Therapeutics (NASDAQ:SMMT) had its "buy" rating reaffirmed by analysts at Guggenheim. They now have a $40.00 price target on the stock.

Report

10/22

09:13 am

smmt

Rating for SMMT

Low Report

Rating for SMMT

Report

10/22

09:13 am

smmt

Rating for SMMT

Low Report

Rating for SMMT

Report

10/21

08:48 am

smmt

Rating for SMMT

Medium Report

Rating for SMMT

Report

10/21

08:48 am

smmt

Rating for SMMT

Medium Report

Rating for SMMT

Report

10/21

08:04 am

smmt

Summit Therapeutics (NASDAQ:SMMT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock, down previously from $50.00.

Medium Report

Summit Therapeutics (NASDAQ:SMMT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock, down previously from $50.00.

Report

10/20

11:32 am

smmt

Rating for SMMT

Low Report

Rating for SMMT

Report

10/20

11:32 am

smmt

Rating for SMMT

Low Report

Rating for SMMT

Report

10/20

09:53 am

smmt

Summit Therapeutics (NASDAQ:SMMT) had its "market outperform" rating reaffirmed by analysts at JMP Securities. They now have a $40.00 price target on the stock.

Low Report

Summit Therapeutics (NASDAQ:SMMT) had its "market outperform" rating reaffirmed by analysts at JMP Securities. They now have a $40.00 price target on the stock.

Report

10/20

09:53 am

smmt

Summit Therapeutics (NASDAQ:SMMT) had its "market outperform" rating reaffirmed by analysts at JMP Securities. They now have a $40.00 price target on the stock.

Low Report

Summit Therapeutics (NASDAQ:SMMT) had its "market outperform" rating reaffirmed by analysts at JMP Securities. They now have a $40.00 price target on the stock.

Report

10/20

09:37 am

smmt

Rating for SMMT

Low Report

Rating for SMMT

Report

10/20

09:37 am

smmt

Rating for SMMT

Low Report

Rating for SMMT

Report

10/20

07:21 am

smmt

Summit Therapeutics (NASDAQ:SMMT) had its "buy" rating reaffirmed by analysts at Citigroup Inc..

Low Report

Summit Therapeutics (NASDAQ:SMMT) had its "buy" rating reaffirmed by analysts at Citigroup Inc..

Report

9/25

10:17 am

smmt

Summit Therapeutics (NASDAQ:SMMT) had its "buy" rating reaffirmed by analysts at Citigroup Inc..

Low Report

Summit Therapeutics (NASDAQ:SMMT) had its "buy" rating reaffirmed by analysts at Citigroup Inc..

Report

9/18

06:44 am

smmt

Summit Therapeutics (NASDAQ:SMMT) was upgraded by analysts at Barclays PLC to a "strong sell" rating.

Medium Report

Summit Therapeutics (NASDAQ:SMMT) was upgraded by analysts at Barclays PLC to a "strong sell" rating.

Report

9/17

08:05 am

smmt

Summit Therapeutics (NASDAQ:SMMT) is now covered by analysts at Barclays PLC. They set an "underweight" rating and a $13.00 price target on the stock.

Low Report

Summit Therapeutics (NASDAQ:SMMT) is now covered by analysts at Barclays PLC. They set an "underweight" rating and a $13.00 price target on the stock.

Report

9/17

06:58 am

smmt

Rating for SMMT

Low Report

Rating for SMMT

Report

9/17

06:58 am

smmt

Rating for SMMT

Low Report

Rating for SMMT

Report

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.